| Biotech Co.* (Country; Symbol) |
Pharma Co. (Country) |
Type/Product Area | Terms/Details (Date) |
| JUNE | |||
| Adimab Inc.* | Merck & Co. Inc. and Roche (Switzerland) | Entered separate antibody deals with the pharmaceutical companies | Adimab will receive various up-front payments, preclinical milestones and licensing fees; it also is eligible to receive clinical development milestones, commercial milestones and royalties (6/16) |
| Amalyte Pharmaceuticals LLC* | Meiji Seika Kaisha Ltd. (Japan) | Worldwide alliance to discover, develop and commercialize a lead compound, ME3301, and a novel class of dual-acting anti-inflammatory compounds for a variety of applications | Amalyte will have exclusive rights to develop and commercialize collaboration products worldwide, except in Japan and several Asian countries (6/8) |
| Aposense Ltd.* | GlaxoSmithKline plc (UK) | Collaboration to evaluate the potential of Aposense's PET tracer ML-10 in monitoring drug activity in clinical studies of cancer therapies | The project is intended to assess the contribution of ML-10 in accelerating clinical development of cancer therapies (6/8) |
| Catalyst Biosciences Inc.* | Wyeth | Agreement to discover, develop and commercialize Factor VIIa products to treat hemophilia and other bleeding conditions | Catalyst expects to earn $40M or more in payments over the next two years under the deal, including $21M up front (6/30) |
| Celera Corp. (CRA) | Bayer Schering Pharma AG (Germany) | Exclusive license deal providing Bayer with access to five cancer-related targets for therapeutic development and in vivo diagnostic imaging | Celera gets a one-time access fee and can receive milestones upon certain development and commercial achievements, plus royalties (6/29) |
| Cerep SA (France; Paris:CER) | Eli Lilly and Co. | Agreement for its expanded kinase assay platform for research into undisclosed drug targets | The agreement builds on a prior agreement between the two companies for access to Cerep's GPCRs portfolio (6/15) |
| Chroma Therapeutics Ltd.* (UK) | GlaxoSmithKline plc (UK) | Agreement for Chroma to apply its chemical motif technology for targeting small molecules directly into macrophages, to develop treatments for autoimmune and other inflammatory diseases | The collaboration involves four programs currently at the discovery stage; the deal is worth $1B if all four reach the market and achieve specified levels of sales (6/23) |
| Concert Pharmaceuticals Inc.* | GlaxoSmithKline plc (UK) | Multiproduct collaboration that includes CTP-518, an HIV protease inhibitor, and the application of Concert's deuterium chemistry platform to three undisclosed GSK compounds | Concert gets $35M up front, including a $16.7M equity investment; development, regulatory and commercial milestones could push the deal to more than $1B (6/2) |
| DiaGenic ASA (Norway; OSLO: DIAG) | Merz Pharmaceuticals GmbH (Germany) | Option agreement to gain access to biomarkers for mild cognitive impairment | Merz also will receive an option for non-exclusive rights to further biomarkers; financial details were not disclosed (6/24) |
| Geron Corp. (GERN) | GE Healthcare (UK; unit of General Electric Co.) | Global exclusive license and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells for use in drug discovery, development and toxicity screening | Financial terms were not disclosed (6/30) |
| Merck & Co. Inc.*** | AstraZeneca plc (UK) | Collaboration to determine the efficacy of a joint regimen of compounds from each company in treating cancer in a Phase I trial | Data suggests that MK-2206 from Merck and AZD6244 from AstraZeneca may be more effective if dosed together; the companies will share co-administration expenses for the trial (6/1) |
| NeurogesX Inc. (NGSX) | Astellas Pharma Inc. (Japan) | Agreement for European rights to Qutenza | The deal is potentially worth $145.5M, including up-front, milestone and option fees, and double-digit royalties on sales (6/22) |
| Novavax Inc. (NVAX) | ROVI Pharmaceuticals (Spain) | Agreement to license Novavax's recombinant virus-like particle vaccine technology to ROVI | ROVI will use it to create an influenza vaccine solution for the Spanish government under a new $84.2M program (6/30) |
| Orexigen Therapeutics Inc. (OREX) | GlaxoSmithKline plc (UK) | Licensing agreement for intellectual property relating to bupropion | The deal involves up-front and milestone payments (6/11) |
| Paladin Labs Inc. (Canada; TSX:PLB) | Wyeth | Agreement to acquire a bundle of Wyeth products marketed in Canada, including Anacin and Anbesol | Financial terms were not disclosed (6/29) |
| Penwest Pharmaceuticals Co. (PPCO) | Otsuka Pharmaceutical Co. Ltd. (Japan) | Research and development agreement to develop a formulation of an undisclosed Otsuka compound using Penwest's TIMERx drug delivery technology | Penwest will receive undisclosed fees and payments (6/17) |
| Raptor Pharmaceuticals Corp. (OTC BB: RPTP) | F. Hoffmann-La Roche Ltd. (Switzerland) | Collaboration to evaluate Raptor's NeuroTrans platform for therapeutic delivery across the blood-brain barrier | Roche gets exclusive worldwide rights to NeuroTrans for delivery of diagnostic and therapeutic molecules and will fund studies of select molecules attached to the platform (6/9) |
| Regeneron Pharmaceuticals Inc. (REGN) | Novartis AG (Switzerland) | License agreement relating to two antibody programs | Regeneron had the right to opt in on Novartis' interleukin-1 antibody, and Novartis had the right to opt in on Regeneron's second-generation interleukin-1 Trap program; Regeneron waived its right to opt in on the anti-interleukin antibody canakinumab and will instead receive royalties, while Novartis will receive royalties on the second-generation interleukin-1 Trap program (6/11) |
| Rexahn Pharmaceuticals Inc. (AMEX:RNN) | Undisclosed big pharmaceutical firm | Exclusive collaboration and option for a license agreement for the development of RX-3117, a small-molecule nucleoside cancer compound | If the pharma firm elects to proceed, Rexahn would receive up-front payments in the form of equity investments, plus milestones and royalties on any product sales (6/29) |
| Valeant Pharmaceuticals International (NYSE:VRX) | Schering-Plough Corp. | Exclusive option agreement for taribavirin, which is in Phase II development for chronic hepatitis C, in Japan | Upon exercising the option and entering into the exclusive license agreement, Schering-Plough would provide a $2M up-front payment to Valeant and pay mid- single-digit royalties on net sales of taribavirin in Japan (6/1) |
| Vitae Pharmaceuticals Inc.* | Boehringer Ingelheim GmbH (Germany) | Deal aimed at disease-modifying drugs against Alzheimer's disease | The deal is worth $42M in cash, an equity investment and research funding, as well as $200M in pre-commercial milestones for the first compound (6/15) |
| Xenon Pharmaceuticals Inc.* | Merck & Co. Inc. | Cardiovascular drug discovery partnership | Deal could bring in up to $94.5M for the first therapeutic target and up to $89.5M for each subsequent target that is secreted for drug discovery (6/11) |
| JULY | |||
| Depomed Inc. (DEPO) | Merck & Co. Inc. | Licensing agreement for certain patents directed to metformin extended-release technology to develop fixed-dose combinations of DPP-4 inhibitor Januvia and extended-release metformin | Merck gets a nonexclusive license plus other rights to certain Depomed patents in exchange for a $10M up-front fee; Depo-med also is eligible to receive a milestone payment upon filing a new drug application for a therapeutic candidate, as well as modest royalties on product sales (7/22) |
| Elan Corp. plc (Ireland; NYSE:ELN) | Johnson & Johnson | Agreement under which J&J will make a $1.5B investment in exchange for a stake in Elan, transferring key Alzheimer's programs, including Phase III bapineu-zumab | A new J&J subsidiary will be formed for the immunotherapy program, as well as a Phase II subcutaneous formulation and a vaccine for Alzheimer's; the parties will own 50%, while Wyeth will own the other 50%; J&J is making an initial commitment of up to $500M (7/2) |
| Flamel Technologies SA (France; FLML) | Baxter International Inc. | Agreement to formulate controlled-release applications of blood-clotting factor replacement therapies using Flamel's Medusa technology | Flamel will receive technology access fees totaling $3.5M; Baxter will pay all development costs for the program and will have an exclusive right to negotiate a license to the Medusa platform (7/13) |
| Gilead Sciences Inc. (GILD) | Tibotec Pharmaceuticals Ltd. (unit of Johnson & Johnson) | Partnership to develop another three-in-one pill combining its Truvada with Tibotec's late-stage non-nucleoside reverse transcriptase inhibitor TMC278 | Gilead will provide up to $100.7M to cover Tibotec's development costs; it also negotiated a 30% discount on TMC278 purchased from Tibotec (7/17) |
| GTC Biotherapeutics Inc. (GTCB) | Merrimack Pharmaceuticals Inc. | Exclusive, worldwide rights agreement to recombinant human alpha-fetoprotein for the treatment of autoimmune diseases | GTC will receive an initial inventory of bulk drug substance for use in clinical studies; it also will assume control of the transgenic goats that express rhAFP in their milk (7/8) |
| Novavax Inc. (NVAX) | Cadila Pharmaceuticals Ltd. (India) | Joint venture agreement to form CPL Biologicals Pvt. Ltd. to develop and manufacture vaccines, biological therapeutics and diagnostics in India | CPL also will establish manufacturing facilities in India and will develop, produce and sell products such as a seasonal influenza vaccine and potentially other vaccines against dengue fever and chikungunya fever based on Novavax's virus-like particle vaccine technology (7/9) |
| Portola Pharmaceuticals Inc.* | Merck & Co. Inc. | Companies agreed to a deal for the Phase II anticoagulant betrixaban | The deal calls for Portola to receive $50M up front, $420M in potential milestone payments and double-digit royalties on worldwide sales; Portola retains the option to co-fund Phase III trials in exchange for U.S. co-promotion rights and higher royalties (7/9) |
| Regimmune Corp.* | Astellas Pharma Inc. (Japan) | Vaccine platform research and development deal | The partnership will combine Regimmune's immune liposome technology with Astellas' screening and development capabilities (7/22) |
|
Notes: # The information in the chart does not cover agricultural agreements or those between biotech companies. * Private companies are indicated with an asterisk.*** Pharmaceutical company deal included in this chart due to its relevance to the biotech industry. Unless otherwise noted, stock symbols listed are on the Nasdaq market.AMEX = American Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | |||